APD811 for Pulmonary Arterial Hypertension
APD811, our lead drug candidate for the treatment of pulmonary arterial hypertension, or PAH, is a selective agonist of the prostanoid IP receptor and is in preclinical development.
IP receptor agonists are among the treatments administered as standard of care for advanced PAH. IP agonists improve mortality and exercise tolerance in PAH patients, but currently available IP agonists are rapidly metabolized and have poor oral bioavailability. Consequently, currently available IP agonists need to be administered frequently or continuously through intravenous, subcutaneous or inhaled means. We believe APD811 has the potential to improve the standard of care for PAH by providing an oral, once-daily form of administration with clinical benefits similar to currently available treatments.
Our product candidates have not been approved by the U.S. Food and Drug Administration or any international regulatory agency.
(This page was last updated: January 5, 2010. Additional information regarding Arena is available in its SEC filings.)
